Tirzepatide
30mg
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This 39-amino acid synthetic peptide is based on the native GIP sequence with modifications that confer GLP-1 receptor co-agonism. A C20 fatty diacid moiety linked through a glutamic acid and two mini-PEG spacers enhances albumin binding, resulting in a half-life suitable for once-weekly dosing. Tirzepatide has demonstrated superior glycemic control and weight reduction compared to selective GLP-1 receptor agonists in clinical trials.
Pricing
Mechanism of Action
Tirzepatide engages both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) with a bias toward GIPR agonism (~5:1 ratio). GIPR activation in adipose tissue modulates lipid storage and adipokine secretion, while central GIPR signaling may contribute to appetite suppression independently of GLP-1 pathways. The combined receptor engagement produces synergistic effects on insulin secretion, glucagon suppression, and energy expenditure that exceed those of selective GLP-1R agonism alone.
Properties
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.45 Da
Half-Life
~5 days
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Research Applications
References & Citations
(3)Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, et al.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
Malhotra A, Grunstein RR, et al.
Related Products
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.